[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ling Zhiqiang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100633291","ganoderma-spores-modulate-the-gut-brain-axis-100633291",false,"NCT07524777","Ganoderma Spores Modulate the Gut-Brain Axis","Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Outpatients at Zhejiang Cancer Hospital with histologically confirmed papillary thyroid carcinoma (post-surgery) and depressive symptoms (HAMD-24 score ≥ 8, confirmed by a clinical psychologist).\n* Han Chinese ethnicity.\n* No history of depression or other psychiatric disorders.\n* Age 18-80 years.\n* Female.\n\nExclusion Criteria:\n\n* Suffering from other gastrointestinal system diseases.\n* History of gastrointestinal surgery prior to intervention.\n* Including those with other concurrent malignancies requiring chemotherapy, radiotherapy, biological therapy, or traditional Chinese medicine treatment.\n* Received antibiotic treatment or microecological modulators within 3 months prior to intervention.\n* Acute intestinal obstruction.\n* Patients who are currently taking antidepressant medication, or those whom the investigators judge require immediate initiation of antidepressant medication treatment.\n* Organic brain diseases, brain trauma.\n* History of psychiatric disorders, use of psychoactive substances (e.g., drugs).\n* Severe liver or kidney dysfunction.\n* Pregnancy or lactation.","FEMALE","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g\u002Fday) or matched placebo.",[27,28],"Depression","Thyroid Cancer","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2026-04-11",{"date":37,"type":21},"2026-08-31",{"name":39,"class":40},"Ling Zhiqiang","OTHER",""]